Vaccines for established cancer: overcoming the challenges posed by immune evasion

[1]  Angela M Bodles-Brakhop,et al.  Tapping the Potential of DNA Delivery with Electroporation for Cancer Immunotherapy. , 2015, Current topics in microbiology and immunology.

[2]  S. H. van der Burg,et al.  Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses , 2016, Science Translational Medicine.

[3]  J. Ahn,et al.  Pembrolizumab for the treatment of non-small cell lung cancer , 2016, Expert opinion on biological therapy.

[4]  S. H. van der Burg,et al.  Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response , 2016, Clinical Cancer Research.

[5]  Michael Dallas,et al.  Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial , 2015, The Lancet.

[6]  Suzanne P. M. Welten,et al.  The Quantity of Autocrine IL-2 Governs the Expansion Potential of CD8+ T Cells , 2015, The Journal of Immunology.

[7]  P. B. van Driel,et al.  Combination of Photodynamic Therapy and Specific Immunotherapy Efficiently Eradicates Established Tumors , 2015, Clinical Cancer Research.

[8]  S. H. van der Burg,et al.  A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  A. Ladányi,et al.  Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma , 2015, Pigment cell & melanoma research.

[10]  S. H. van der Burg,et al.  A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer , 2015, Oncotarget.

[11]  Joel H Collier,et al.  Supramolecular peptide vaccines: tuning adaptive immunity. , 2015, Current opinion in immunology.

[12]  I. Melero,et al.  Evolving synergistic combinations of targeted immunotherapies to combat cancer , 2015, Nature Reviews Cancer.

[13]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[14]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[15]  T. Aparicio,et al.  PD-1 blockade in tumors with mismatch-repair deficiency , 2015 .

[16]  B. Brors,et al.  Thymic B Cells Are Licensed to Present Self Antigens for Central T Cell Tolerance Induction. , 2015, Immunity.

[17]  B. Kyewski,et al.  Central T cell tolerance: Identification of tissue-restricted autoantigens in the thymus HLA-DR peptidome. , 2015, Journal of autoimmunity.

[18]  J. Castle,et al.  Mutant MHC class II epitopes drive therapeutic immune responses to cancer , 2015, Nature.

[19]  S. H. van der Burg,et al.  Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression , 2015, Cancer Immunology Research.

[20]  D. Pardoll,et al.  STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade , 2015, Science Translational Medicine.

[21]  P. Allavena,et al.  The interaction of anticancer therapies with tumor-associated macrophages , 2015, The Journal of experimental medicine.

[22]  S. Rosenberg,et al.  Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.

[23]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[24]  A. Arina,et al.  Myeloid-derived suppressor cell impact on endogenous and adoptively transferred T cells. , 2015, Current opinion in immunology.

[25]  S. Gnjatic,et al.  Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity , 2015, Front. Immunol..

[26]  R. McLendon,et al.  Tetanus toxoid and CCL3 improve DC vaccines in mice and glioblastoma patients , 2015, Nature.

[27]  H. Ditzel,et al.  Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non–Small Cell Lung Cancer , 2015, Clinical Cancer Research.

[28]  E. Tartour,et al.  VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors , 2015, The Journal of experimental medicine.

[29]  E. Jaffee,et al.  PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors , 2015, Journal of immunotherapy.

[30]  I. Endo,et al.  Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes , 2014, International journal of oncology.

[31]  S. H. van der Burg,et al.  Therapeutic cancer vaccines. , 2010, The Journal of clinical investigation.

[32]  Michael R Stratton,et al.  High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma , 2014, Nature Medicine.

[33]  J. Wolchok,et al.  Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. , 2015, The New England journal of medicine.

[34]  S. H. van der Burg,et al.  Vaccine-Induced Tumor Necrosis Factor–Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death , 2014, Clinical Cancer Research.

[35]  F. Garrido,et al.  Metastases in immune-mediated dormancy: a new opportunity for targeting cancer. , 2014, Cancer research.

[36]  Maxim N. Artyomov,et al.  Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens , 2014, Nature.

[37]  S. H. van der Burg,et al.  Dominant contribution of the proteasome and metalloproteinases to TAP-independent MHC-I peptide repertoire. , 2014, Molecular immunology.

[38]  H. Hollema,et al.  Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer , 2014, Oncoimmunology.

[39]  J. Sheridan,et al.  In vivo maintenance of human regulatory T cells during CD25 blockade , 2014, Journal of Neuroimmunology.

[40]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[41]  Özlem Türeci,et al.  mRNA-based therapeutics — developing a new class of drugs , 2014, Nature Reviews Drug Discovery.

[42]  I. Melero,et al.  Therapeutic vaccines for cancer: an overview of clinical trials , 2014, Nature Reviews Clinical Oncology.

[43]  D. Gomez,et al.  Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors? , 2014, Cancer Immunology Research.

[44]  S. H. van der Burg,et al.  Alterations in classical and nonclassical HLA expression in recurrent and progressive HPV‐induced usual vulvar intraepithelial neoplasia and implications for immunotherapy , 2014, International journal of cancer.

[45]  O. Finn.  Vaccines for Cancer Prevention: A Practical and Feasible Approach to the Cancer Epidemic , 2014, Cancer Immunology Research.

[46]  C. Breitbach,et al.  Going viral with cancer immunotherapy , 2014, Nature Reviews Cancer.

[47]  D. Filippov,et al.  N-tetradecylcarbamyl lipopeptides as novel agonists for Toll-like receptor 2. , 2014, Journal of medicinal chemistry.

[48]  T. Wu,et al.  Conjugation of a TLR7 agonist and antigen enhances protection in the S. pneumoniae murine infection model. , 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[49]  P. Altevogt,et al.  Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30. , 2014, Cancer research.

[50]  D. Alizadeh,et al.  Chemotherapeutic targeting of cancer-induced immunosuppressive cells. , 2014, Cancer research.

[51]  P. Dessen,et al.  PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation , 2014, The Journal of experimental medicine.

[52]  D. Filippov,et al.  Efficient Induction of Antitumor Immunity by Synthetic Toll-like Receptor Ligand–Peptide Conjugates , 2014, Cancer Immunology Research.

[53]  T. Karrison,et al.  Adoptively Transferred Immune T Cells Eradicate Established Tumors despite Cancer-Induced Immune Suppression , 2014, The Journal of Immunology.

[54]  N. Nagarajan,et al.  Monitoring peptide processing for MHC class I molecules in the endoplasmic reticulum. , 2014, Current opinion in immunology.

[55]  Y. Takeda,et al.  Wilms Tumor Gene (WT1) Peptide–based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer , 2014, Journal of immunotherapy.

[56]  S. H. van der Burg,et al.  Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer , 2014, Expert review of vaccines.

[57]  Hong Wang,et al.  PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines. , 2013, Cancer research.

[58]  M. Oka,et al.  A Phase I Clinical Trial of Vaccination With KIF20A-derived Peptide in Combination With Gemcitabine For Patients With Advanced Pancreatic Cancer , 2013, Journal of immunotherapy.

[59]  B. Fox,et al.  Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells , 2013, European journal of immunology.

[60]  R. Ferris,et al.  EGFR-mediated tumor immunoescape: The imbalance between phosphorylated STAT1 and phosphorylated STAT3 , 2014 .

[61]  S. Aamdal,et al.  Immune escape of cancer cells with beta2‐microglobulin loss over the course of metastatic melanoma , 2014, International journal of cancer.

[62]  C. Meyer,et al.  Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab , 2014, Cancer Immunology, Immunotherapy.

[63]  S. H. van der Burg,et al.  The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study , 2014, Cancer Immunology, Immunotherapy.

[64]  B. Levine,et al.  Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells , 2013, Clinical Cancer Research.

[65]  S. H. van der Burg,et al.  Tumor‐infiltrating CD14‐positive myeloid cells and CD8‐positive T‐cells prolong survival in patients with cervical carcinoma , 2013, International journal of cancer.

[66]  L. Butterfield.  Dendritic Cells in Cancer Immunotherapy Clinical Trials: Are We Making Progress? , 2013, Front. Immunol..

[67]  J. Marshall,et al.  A Randomized Phase II Study of Immunization With Dendritic Cells Modified With Poxvectors Encoding CEA and MUC1 Compared With the Same Poxvectors Plus GM-CSF for Resected Metastatic Colorectal Cancer , 2013, Annals of surgery.

[68]  M. Stratton,et al.  Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  S. H. van der Burg,et al.  New Role of Signal Peptide Peptidase To Liberate C-Terminal Peptides for MHC Class I Presentation , 2013, The Journal of Immunology.

[70]  D. Linehan,et al.  Targeting tumor-infiltrating macrophages to combat cancer. , 2013, Immunotherapy.

[71]  S. R. Pedersen,et al.  Comparison of Vaccine-Induced Effector CD8 T Cell Responses Directed against Self- and Non–Self-Tumor Antigens: Implications for Cancer Immunotherapy , 2013, The Journal of Immunology.

[72]  Jason B. Williams,et al.  Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells , 2013, Science Translational Medicine.

[73]  N. Ibrahim,et al.  Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial , 2013, Journal of Cancer.

[74]  G. Coukos,et al.  Deciphering and reversing tumor immune suppression. , 2013, Immunity.

[75]  L. Zitvogel,et al.  Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. , 2013, Immunity.

[76]  G. Hartmann,et al.  Review Turning Tumors into Vaccines: Co-opting the Innate Immune System , 2022 .

[77]  E. Jaffee,et al.  Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

[78]  D. Munn,et al.  Antigen-Specific Bacterial Vaccine Combined with Anti-PD-L1 Rescues Dysfunctional Endogenous T Cells to Reject Long-Established Cancer , 2013, Cancer Immunology Research.

[79]  G. Freeman,et al.  Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. , 2013, Cancer research.

[80]  Jimmy Lin,et al.  Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T cells , 2013, Nature Medicine.

[81]  J. Thiery,et al.  EMT impairs breast carcinoma cell susceptibility to CTL-mediated lysis through autophagy induction , 2013, Autophagy.

[82]  S. H. van der Burg,et al.  Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. , 2013, Cancer research.

[83]  Tae Woo Kim,et al.  Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. , 2013, Cancer research.

[84]  HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial , 2013, Journal of Translational Medicine.

[85]  S. H. van der Burg,et al.  Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer. , 2013, Seminars in immunology.

[86]  S. H. van der Burg,et al.  Addition of interferon‐α to the p53‐SLP® vaccine results in increased production of interferon‐γ in vaccinated colorectal cancer patients: A phase I/II clinical trial , 2013, International journal of cancer.

[87]  D. Munn,et al.  Indoleamine 2,3 dioxygenase and metabolic control of immune responses. , 2013, Trends in immunology.

[88]  Masashi Kato,et al.  Antitumor Effect of Paclitaxel Is Mediated by Inhibition of Myeloid-Derived Suppressor Cells and Chronic Inflammation in the Spontaneous Melanoma Model , 2013, The Journal of Immunology.

[89]  C. Benedict,et al.  Clinical targeting of the TNF and TNFR superfamilies , 2013, Nature Reviews Drug Discovery.

[90]  Sunil Singhal,et al.  Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery , 2012, Proceedings of the National Academy of Sciences.

[91]  R. Schoen,et al.  MUC1 Vaccine for Individuals with Advanced Adenoma of the Colon: A Cancer Immunoprevention Feasibility Study , 2012, Cancer Prevention Research.

[92]  J. Landsberg,et al.  Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation , 2012, Nature.

[93]  Yusuke Nakamura,et al.  Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. , 2012, International journal of oncology.

[94]  P. Romero,et al.  Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. , 2012, Cancer research.

[95]  S. Heys,et al.  Characterisation of tumour-infiltrating macrophages: impact on response and survival in patients receiving primary chemotherapy for breast cancer , 2012, Breast Cancer Research and Treatment.

[96]  Hiroaki Tanaka,et al.  Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival , 2012, Nature Medicine.

[97]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[98]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[99]  A. DeMichele,et al.  CD25 Blockade Depletes and Selectively Reprograms Regulatory T Cells in Concert with Immunotherapy in Cancer Patients , 2012, Science Translational Medicine.

[100]  A. Stojadinovic,et al.  Clinical trial results of the HER‐2/neu (E75) vaccine to prevent breast cancer recurrence in high‐risk patients , 2012, Cancer.

[101]  I. Lowy,et al.  Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.

[102]  A. Dalgleish,et al.  An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[103]  N. Nagarajan,et al.  Non-classical MHC class Ib-restricted cytotoxic T cells monitor antigen processing in the endoplasmic reticulum , 2012, Nature Immunology.

[104]  S. H. van der Burg,et al.  The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools , 2012, Cancer Immunology, Immunotherapy.

[105]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[106]  G. Missale,et al.  Immunological and Molecular Correlates of Disease Recurrence after Liver Resection for Hepatocellular Carcinoma , 2012, PloS one.

[107]  J. Sprent,et al.  The role of interleukin-2 during homeostasis and activation of the immune system , 2012, Nature Reviews Immunology.

[108]  D. Filippov,et al.  TLR ligand-peptide conjugate vaccines: toward clinical application. , 2012, Advances in immunology.

[109]  S. H. van der Burg,et al.  Mechanisms of peptide vaccination in mouse models: tolerance, immunity, and hyperreactivity. , 2012, Advances in immunology.

[110]  J. Saunders,et al.  Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine , 2012, Cancer Immunology, Immunotherapy.

[111]  R. Vance,et al.  STING and the innate immune response to nucleic acids in the cytosol , 2012, Nature Immunology.

[112]  B. Seliger,et al.  Novel insights into the molecular mechanisms of HLA class I abnormalities , 2012, Cancer Immunology, Immunotherapy.

[113]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[114]  P. Validire,et al.  Different Expression Levels of the TAP Peptide Transporter Lead to Recognition of Different Antigenic Peptides by Tumor-Specific CTL , 2011, The Journal of Immunology.

[115]  F. Marincola,et al.  IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. , 2011, The Journal of clinical investigation.

[116]  T. van Hall,et al.  A novel category of antigens enabling CTL immunity to tumor escape variants: Cinderella antigens , 2011, Cancer Immunology, Immunotherapy.

[117]  S. H. van der Burg,et al.  Peptide transporter TAP mediates between competing antigen sources generating distinct surface MHC class I peptide repertoires , 2011, European journal of immunology.

[118]  Niren Kapoor,et al.  The Unfolded Protein Response (UPR)-activated Transcription Factor X-box-binding Protein 1 (XBP1) Induces MicroRNA-346 Expression That Targets the Human Antigen Peptide Transporter 1 (TAP1) mRNA and Governs Immune Regulatory Genes* , 2011, The Journal of Biological Chemistry.

[119]  H. Hollema,et al.  Potentiation of a P53-SLP vaccine by cyclophosphamide in ovarian cancer, A single ARM phase II study , 2011 .

[120]  K. Murphy,et al.  Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells , 2011, The Journal of experimental medicine.

[121]  S. Pascolo,et al.  Gemcitabine depletes regulatory T‐cells in human and mice and enhances triggering of vaccine‐specific cytotoxic T‐cells , 2011, International journal of cancer.

[122]  Xiang Huang,et al.  Preconditioning chemotherapy with paclitaxel and cisplatin enhances the antitumor activity of cytokine induced‐killer cells in a murine lung carcinoma model , 2011, International journal of cancer.

[123]  S. H. van der Burg,et al.  M2 Macrophages Induced by Prostaglandin E2 and IL-6 from Cervical Carcinoma Are Switched to Activated M1 Macrophages by CD4+ Th1 Cells , 2011, The Journal of Immunology.

[124]  Naveena Singh,et al.  Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer , 2011, Clinical Cancer Research.

[125]  S. H. van der Burg,et al.  HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes , 2011, Proceedings of the National Academy of Sciences.

[126]  H. Rammensee,et al.  Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[127]  R. Gavioli,et al.  IFN-α boosts epitope cross-presentation by dendritic cells via modulation of proteasome activity. , 2011, Immunobiology.

[128]  T. van Hall,et al.  Strategies to counteract MHC-I defects in tumors. , 2011, Current opinion in immunology.

[129]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[130]  S. H. van der Burg,et al.  Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha , 2011, Cancer Immunology, Immunotherapy.

[131]  Yanping Zhang,et al.  The role of interleukin‐12 on modulating myeloid‐derived suppressor cells, increasing overall survival and reducing metastasis , 2011, Immunology.

[132]  S. H. van der Burg,et al.  Immunotherapy for persistent viral infections and associated disease. , 2011, Trends in immunology.

[133]  M. Willson,et al.  CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans , 2011 .

[134]  J. Wolchok,et al.  Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs. , 2011, Journal of veterinary internal medicine.

[135]  J. Karbach,et al.  Efficient In vivo Priming by Vaccination with Recombinant NY-ESO-1 Protein and CpG in Antigen Naïve Prostate Cancer Patients , 2010, Clinical Cancer Research.

[136]  S. H. van der Burg,et al.  CD8+ T Cell Responses against TAP-Inhibited Cells Are Readily Detected in the Human Population , 2010, The Journal of Immunology.

[137]  L. Sherman,et al.  CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. , 2010, Cancer research.

[138]  B. Nelson,et al.  CD20+ B Cells: The Other Tumor-Infiltrating Lymphocytes , 2010, The Journal of Immunology.

[139]  S. H. van der Burg,et al.  Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm. , 2010, Cancer research.

[140]  Raymond Sawaya,et al.  Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[141]  R. Coffman,et al.  Vaccine adjuvants: putting innate immunity to work. , 2010, Immunity.

[142]  S. Rosenberg,et al.  Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma , 2010, Journal of immunotherapy.

[143]  A. Mantovani,et al.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm , 2010, Nature Immunology.

[144]  R. Hipskind,et al.  Oxidative Phosphorylation Induces De Novo Expression of the MHC Class I in Tumor Cells through the ERK5 Pathway , 2010, The Journal of Immunology.

[145]  P. Natali,et al.  Dacarbazine treatment before peptide vaccination enlarges T-cell repertoire diversity of melan-a-specific, tumor-reactive CTL in melanoma patients. , 2010, Cancer research.

[146]  D. Gilvary,et al.  A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers , 2010, Clinical Cancer Research.

[147]  F. Garrido,et al.  “Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy , 2010, International journal of cancer.

[148]  S. Bicciato,et al.  Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. , 2010, Immunity.

[149]  J. M. van der Hulst,et al.  Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses , 2010, Proceedings of the National Academy of Sciences.

[150]  David M. Mosser,et al.  Exploring the full spectrum of macrophage activation , 2010, Nature Reviews Immunology.

[151]  M. Geller,et al.  Chemotherapy Induces Macrophage Chemoattractant Protein-1 Production in Ovarian Cancer , 2010, International Journal of Gynecologic Cancer.

[152]  J. Vincent,et al.  5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. , 2010, Cancer research.

[153]  J. Mulé,et al.  Blockade of Programmed Death Ligand 1 Enhances the Therapeutic Efficacy of Combination Immunotherapy against Melanoma , 2010, The Journal of Immunology.

[154]  S. Altiok,et al.  Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. , 2010, The Journal of clinical investigation.

[155]  J. M. van der Hulst,et al.  An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer. , 2010, Cancer research.

[156]  H. Kitchener,et al.  Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia , 2010, British Journal of Cancer.

[157]  D. Qian,et al.  CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel‐induced cytotoxicity , 2010, The Prostate.

[158]  P. Sinha,et al.  Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. , 2010, Cancer research.

[159]  Lunxu Liu,et al.  The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time , 2010, BMC Cancer.

[160]  S. H. van der Burg,et al.  Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. , 2009, The New England journal of medicine.

[161]  Steven Piantadosi,et al.  Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[162]  M. Koch,et al.  Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. , 2009, The Journal of clinical investigation.

[163]  M. Smyth,et al.  Cyclophosphamide Chemotherapy Sensitizes Tumor Cells to TRAIL-Dependent CD8 T Cell-Mediated Immune Attack Resulting in Suppression of Tumor Growth , 2009, PloS one.

[164]  J. Landsberg,et al.  Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy. , 2009, Cancer research.

[165]  A. Raghavan,et al.  Gene Regulation and Chromatin Remodeling by IL-12 and Type I IFN in Programming for CD8 T Cell Effector Function and Memory1 , 2009, The Journal of Immunology.

[166]  C. Liu,et al.  IFN-α Enhances Peptide Vaccine-Induced CD8+ T Cell Numbers, Effector Function, and Antitumor Activity1 , 2009, The Journal of Immunology.

[167]  T. Gajewski,et al.  Costimulatory and coinhibitory receptors in anti‐tumor immunity , 2009, Immunological reviews.

[168]  J. Sin,et al.  Adoptive transfer of human papillomavirus E7-specific CTL enhances tumor chemoresponse through the perforin/granzyme-mediated pathway. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[169]  D. Filippov,et al.  Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity , 2009, Proceedings of the National Academy of Sciences.

[170]  A. McMichael,et al.  Comparing Pooled Peptides with Intact Protein for Accessing Cross-presentation Pathways for Protective CD8+ and CD4+ T Cells* , 2009, Journal of Biological Chemistry.

[171]  P. Bradding,et al.  Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival , 2009, European Respiratory Journal.

[172]  Antonio Polley,et al.  Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection , 2009, Nature Immunology.

[173]  F. Marincola,et al.  Chemotherapy enhances vaccine‐induced antitumor immunity in melanoma patients , 2009, International journal of cancer.

[174]  B. Seliger,et al.  HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice , 2009, Cancer Immunology, Immunotherapy.

[175]  R. Gopaul,et al.  Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. , 2008, Cancer research.

[176]  E. Unanue,et al.  Batf3 Deficiency Reveals a Critical Role for CD8α+ Dendritic Cells in Cytotoxic T Cell Immunity , 2008, Science.

[177]  A. Stojadinovic,et al.  Optimal dose and schedule of an HER‐2/neu (E75) peptide vaccine to prevent breast cancer recurrence , 2008, Cancer.

[178]  P. van Endert,et al.  Altered expression of endoplasmic reticulum aminopeptidases ERAP1 and ERAP2 in transformed non‐lymphoid human tissues , 2008, Journal of cellular physiology.

[179]  J. M. van der Hulst,et al.  Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasia , 2008, International journal of cancer.

[180]  F. Garrido,et al.  Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy , 2008, Immunogenetics.

[181]  T. Lawrence,et al.  “Re-educating” tumor-associated macrophages by targeting NF-κB , 2008, The Journal of experimental medicine.

[182]  C. Chuang,et al.  Pretreatment with Cisplatin Enhances E7-Specific CD8+ T-Cell–Mediated Antitumor Immunity Induced by DNA Vaccination , 2008, Clinical Cancer Research.

[183]  C. Melief,et al.  Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines , 2008, Nature Reviews Cancer.

[184]  S. H. van der Burg,et al.  Tumor-specific regulatory T cells in cancer patients. , 2008, Human immunology.

[185]  P. Courtoy,et al.  Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. , 2008, Immunity.

[186]  L. Sherman,et al.  Tumor-Specific CD4+ T Cells Render the Tumor Environment Permissive for Infiltration by Low-Avidity CD8+ T Cells1 , 2008, The Journal of Immunology.

[187]  J. M. van der Hulst,et al.  Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA‐DQ and –DP as a restriction element , 2008, International journal of cancer.

[188]  T. Tomasi,et al.  Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells , 2008, Cancer Immunology, Immunotherapy.

[189]  Lloyd J. Old,et al.  Adaptive immunity maintains occult cancer in an equilibrium state , 2007, Nature.

[190]  M. Colombo,et al.  Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy , 2007, Nature Reviews Cancer.

[191]  R. Offringa,et al.  Induction of protective CTL immunity against peptide transporter TAP-deficient tumors through dendritic cell vaccination. , 2007, Cancer research.

[192]  S. H. van der Burg,et al.  Distinct Uptake Mechanisms but Similar Intracellular Processing of Two Different Toll-like Receptor Ligand-Peptide Conjugates in Dendritic Cells* , 2007, Journal of Biological Chemistry.

[193]  J. M. van der Hulst,et al.  Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens , 2007, Proceedings of the National Academy of Sciences.

[194]  Yuji Sato,et al.  Immunological evaluation of personalized peptide vaccination in combination with a 5‐fluorouracil derivative (TS‐1) for advanced gastric or colorectal carcinoma patients , 2007, Cancer science.

[195]  N. Gay,et al.  Structure and function of Toll receptors and their ligands. , 2007, Annual review of biochemistry.

[196]  Michael Y. Gerner,et al.  Signal 3 Availability Limits the CD8 T Cell Response to a Solid Tumor1 , 2007, The Journal of Immunology.

[197]  H. Nisenbaum,et al.  Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. , 2007, Cancer research.

[198]  Sebastian Amigorena,et al.  In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor , 2007, The Journal of experimental medicine.

[199]  S. H. van der Burg,et al.  Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists. , 2007, Vaccine.

[200]  J. Sin,et al.  Therapeutic Synergy of Human Papillomavirus E7 Subunit Vaccines plus Cisplatin in an Animal Tumor Model: Causal Involvement of Increased Sensitivity of Cisplatin-Treated Tumors to CTL-Mediated Killing in Therapeutic Synergy , 2007, Clinical Cancer Research.

[201]  Ekaterina S Jordanova,et al.  High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. , 2007, Cancer research.

[202]  F. Garrido,et al.  HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination , 2007, Cancer Immunology, Immunotherapy.

[203]  B. Chauffert,et al.  Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients , 2007, Cancer Immunology, Immunotherapy.

[204]  M. Koch,et al.  Tumor Infiltrating T Lymphocytes in Colorectal Cancer: Tumor-Selective Activation and Cytotoxic Activity In Situ , 2006, Annals of surgery.

[205]  Marij J P Welters,et al.  Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy. , 2006, Advanced drug delivery reviews.

[206]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[207]  C. Klebanoff,et al.  CD8+ T‐cell memory in tumor immunology and immunotherapy , 2006, Immunological reviews.

[208]  R. Offringa,et al.  Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants , 2006, Nature Medicine.

[209]  S. Steinberg,et al.  A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[210]  G. Bepler,et al.  Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer , 2006, Clinical Cancer Research.

[211]  C. Drake,et al.  Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. , 2006, Blood.

[212]  J. Pollard,et al.  Distinct role of macrophages in different tumor microenvironments. , 2006, Cancer research.

[213]  E. Jordanova,et al.  Frequent HLA class I loss is an early event in cervical carcinogenesis. , 2005, Human immunology.

[214]  L. Kaiser,et al.  Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity , 2005, Clinical Cancer Research.

[215]  C. Figdor,et al.  Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[216]  K. Rock,et al.  Both Dendritic Cells and Macrophages Can Stimulate Naive CD8 T Cells In Vivo to Proliferate, Develop Effector Function, and Differentiate into Memory Cells1 , 2005, The Journal of Immunology.

[217]  R. Offringa,et al.  Expression of a natural tumor antigen by thymic epithelial cells impairs the tumor-protective CD4+ T-cell repertoire. , 2005, Cancer research.

[218]  T. Waldmann,et al.  Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[219]  J. Termini,et al.  Novel conjugates of epitope fusion peptides with CpG-ODN display enhanced immunogenicity and HIV recognition. , 2005, Vaccine.

[220]  E. Pamer,et al.  The Fate of Low Affinity Tumor-Specific CD8+ T Cells in Tumor-Bearing Mice1 , 2005, The Journal of Immunology.

[221]  A. Lanfranco,et al.  CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms , 2004, Molecular and Cellular Biology.

[222]  J. Frelinger,et al.  Induction of Tumor Cell Apoptosis In Vivo Increases Tumor Antigen Cross-Presentation, Cross-Priming Rather than Cross-Tolerizing Host Tumor-Specific CD8 T Cells1 , 2003, The Journal of Immunology.

[223]  Akira Hattori,et al.  An IFN-γ–induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I–presented peptides , 2002, Nature Immunology.

[224]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[225]  V. Engelhard,et al.  Antigens derived from melanocyte differentiation proteins: self‐tolerance, autoimmunity, and use for cancer immunotherapy , 2002, Immunological reviews.

[226]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[227]  S. H. van der Burg,et al.  Established Human Papillomavirus Type 16-Expressing Tumors Are Effectively Eradicated Following Vaccination with Long Peptides1 , 2002, The Journal of Immunology.

[228]  R. Offringa,et al.  Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine , 2001, The Journal of experimental medicine.

[229]  Ira Mellman,et al.  Dendritic Cells Specialized and Regulated Antigen Processing Machines , 2001, Cell.

[230]  R. Ronca,et al.  Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. , 2000, Blood.

[231]  G. Blair,et al.  Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins , 2000, Oncogene.

[232]  P. Ricciardi-Castagnoli,et al.  Immature Dendritic Cells Acquire Cd8+Cytotoxic T Lymphocyte Priming Capacity upon Activation by T Helper Cell–Independent or–Dependent Stimuli , 2000, The Journal of experimental medicine.

[233]  G. Fleuren,et al.  Multiple Genetic Alterations Cause Frequent and Heterogeneous Human Histocompatibility Leukocyte Antigen Class I Loss in Cervical Cancer , 2000, The Journal of experimental medicine.

[234]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[235]  F. Marincola,et al.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.

[236]  R. Offringa,et al.  Immune Escape of Tumors in Vivo by Expression of Cellular Flice-Inhibitory Protein , 1999, The Journal of experimental medicine.

[237]  Robert Tampé,et al.  Down‐regulation of the MHC class I antigen‐processing machinery after oncogenic transformation of murine fibroblasts , 1998, European journal of immunology.

[238]  R. Schwartz.  T cell anergy. , 2003, Annual review of immunology.

[239]  H. Rammensee,et al.  In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine , 1989, Nature.

[240]  S. Ferrone,et al.  Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells. , 1983, Cancer research.

[241]  M. Mihm,et al.  Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations and malignant melanoma. , 1982, Journal of immunology.

[242]  M. S. Fisher,et al.  Immunologic parameters of ultraviolet carcinogenesis. , 1976, Journal of the National Cancer Institute.

[243]  G. Klein,et al.  ANTIGENIC PROPERTIES OF LYMPHOMAS INDUCED BY THE MOLONEY AGENT. , 1964, Journal of the National Cancer Institute.

[244]  R. Prehn,et al.  Immunity to methylcholanthrene-induced sarcomas. , 1957, Journal of the National Cancer Institute.